Masimo (NASDAQ:MASI) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Masimo (NASDAQ:MASI) in a report released on Wednesday morning,Benzinga reports.

Several other research analysts also recently commented on MASI. Piper Sandler lifted their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.

Masimo Stock Down 1.7 %

Shares of NASDAQ:MASI opened at $173.16 on Wednesday. The firm has a market capitalization of $9.27 billion, a PE ratio of 119.42 and a beta of 1.01. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 52-week low of $101.61 and a 52-week high of $180.97. The firm has a fifty day moving average of $169.75 and a 200 day moving average of $141.35.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. As a group, research analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Institutional Trading of Masimo

Large investors have recently modified their holdings of the business. UMB Bank n.a. lifted its holdings in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 123 shares during the period. Blue Trust Inc. lifted its stake in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 71 shares during the period. Trust Co. of Vermont purchased a new stake in Masimo in the fourth quarter worth $33,000. NBC Securities Inc. increased its position in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.